Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QPS Holdings, a GLP/GCP-compliant contract research organization which provides preclinical and clinical research services to pharmaceutical and biotechnology clients, has acquired the Center of Toxicology and Preclinical Sciences (CTPS) from Taiwan's Development Center for Biotechnology (DCB).
Subscribe to our email newsletter
The Taiwan-based CTPS, which is an ISO/IEC 17025 certified, GLP compliant and AAALAC accredited facility specializing in general nonclinical toxicity and safety testing, genetic toxicology, reproductive toxicology, immunotoxicity testing, biocompatibility testing, and DMPK studies, will now become a division of QPS-Taiwan.
QPS-Taiwan president and CEO Vincent Yen said the addition of CTPS to the company’s established bioanalytical and pharmacokinetic expertise will help QPS to provide a one-stop solution to the increasing local and international demand for high quality preclinical services.
QPS vice president and head of Global Safety Assessment and Regulatory Affairs Walter Bee said the addition of the top-notch DCB toxicology unit enhances QPS’ offerings for its clients worldwide.